Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

Simple item page
dc.contributor.authorLi Bassi, Gianluigi
dc.contributor.authorGibbons, Kristen
dc.contributor.authorSuen, Jacky Y.
dc.contributor.authorDalton, Heidi J.
dc.contributor.authorWhite, Nicole
dc.contributor.authorCorley, Amanda
dc.contributor.authorShrapnel, Sally
dc.contributor.authorHinton, Samuel
dc.contributor.authorForsyth, Simon
dc.contributor.authorLaffey, John G.
dc.contributor.authorFan, Eddy
dc.contributor.authorFanning, Jonathon P.
dc.contributor.authorPanigada, Mauro
dc.contributor.authorBartlett, Robert
dc.contributor.authorBrodie, Daniel
dc.contributor.authorBurrell, Aidan
dc.contributor.authorChiumello, Davide
dc.contributor.authorElhazmi, Alyaa
dc.contributor.authorEsperatti, Mariano
dc.contributor.authorGrasselli, Giacomo
dc.contributor.authorHodgson, Carol
dc.contributor.authorIchiba, Shingo
dc.contributor.authorLuna, Carlos
dc.contributor.authorMarwali, Eva
dc.contributor.authorMerson, Laura
dc.contributor.authorMurthy, Srinivas
dc.contributor.authorNichol, Alistair
dc.contributor.authorOgino, Mark
dc.contributor.authorPelosi, Paolo
dc.contributor.authorTorres, Antoni
dc.contributor.authorNg, Pauline Y.
dc.contributor.authorFraser, John F.
dc.date.accessioned2022-05-22T00:03:57Z
dc.date.available2022-05-22T00:03:57Z
dc.date.issued2022-05-17
dc.date.updated2022-05-22T00:03:57Z
dc.description.abstractAbstract Background The role of neuromuscular blocking agents (NMBAs) in coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) is not fully elucidated. Therefore, we aimed to investigate in COVID-19 patients with moderate-to-severe ARDS the impact of early use of NMBAs on 90-day mortality, through propensity score (PS) matching analysis. Methods We analyzed a convenience sample of patients with COVID-19 and moderate-to-severe ARDS, admitted to 244 intensive care units within the COVID-19 Critical Care Consortium, from February 1, 2020, through October 31, 2021. Patients undergoing at least 2 days and up to 3 consecutive days of NMBAs (NMBA treatment), within 48 h from commencement of IMV were compared with subjects who did not receive NMBAs or only upon commencement of IMV (control). The primary objective in the PS-matched cohort was comparison between groups in 90-day in-hospital mortality, assessed through Cox proportional hazard modeling. Secondary objectives were comparisons in the numbers of ventilator-free days (VFD) between day 1 and day 28 and between day 1 and 90 through competing risk regression. Results Data from 1953 patients were included. After propensity score matching, 210 cases from each group were well matched. In the PS-matched cohort, mean (± SD) age was 60.3 ± 13.2 years and 296 (70.5%) were male and the most common comorbidities were hypertension (56.9%), obesity (41.1%), and diabetes (30.0%). The unadjusted hazard ratio (HR) for death at 90 days in the NMBA treatment vs control group was 1.12 (95% CI 0.79, 1.59, p = 0.534). After adjustment for smoking habit and critical therapeutic covariates, the HR was 1.07 (95% CI 0.72, 1.61, p = 0.729). At 28 days, VFD were 16 (IQR 0–25) and 25 (IQR 7–26) in the NMBA treatment and control groups, respectively (sub-hazard ratio 0.82, 95% CI 0.67, 1.00, p = 0.055). At 90 days, VFD were 77 (IQR 0–87) and 87 (IQR 0–88) (sub-hazard ratio 0.86 (95% CI 0.69, 1.07; p = 0.177). Conclusions In patients with COVID-19 and moderate-to-severe ARDS, short course of NMBA treatment, applied early, did not significantly improve 90-day mortality and VFD. In the absence of definitive data from clinical trials, NMBAs should be indicated cautiously in this setting.
dc.identifier.citationCritical Care. 2022 May 17;26(1):141
dc.identifier.doihttps://doi.org/10.1186/s13054-022-03983-5
dc.identifier.urihttp://hdl.handle.net/1880/114693
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.titleEarly short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13054_2022_Article_3983.pdf
Size:
1.58 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Publications